BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH ...
Analyst Faisal Khurshid of Leerink Partners reiterated a Buy rating on Pliant Therapeutics (PLRX – Research Report), retaining the price target of $33.00. Faisal Khurshid has given his Buy rating due ...
Analyst Edward Nash of Canaccord Genuity maintained a Buy rating on Pliant Therapeutics (PLRX – Research Report), retaining the price ...
SOUTH SAN FRANCISCO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: PLRX), today announced that Keith Cummings, M.D., Chief ...
Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) have earned an average recommendation of “Buy” from the nine analysts that are covering the firm, Marketbeat Ratings reports. Eight ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
About Pliant Therapeutics, Inc. Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases.
(MENAFN- GlobeNewsWire - Nasdaq) SOUTH SAN FRANCISCO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that Keith Cummings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback